From Our Support Group Leaders

Explaining myasthenia gravis (MG) to others can be challenging. We asked our support group leaders how they explain MG to people who are unfamiliar with the condition. 

Kelly Aiken

There are two versions of this autoimmune neuromuscular disease. One version is ocular which can cause symptoms such as ptosis, double vision, and blurry vision. The other version is generalized and causes weakness that’s only supposed to affect voluntary skeletal muscles, such as the eyes, neck, shoulders, arms, back, hips, legs, throat, and diaphragm. However, smooth muscles, such as the esophagus or bladder are also known to be affected. Similarly, the throat and diaphragm can experience weakness which can lead to choking or challenges with breathing, people can go into what’s called a ‘crisis” and need medical attention. While crisis survival rates are extremely high, recovery can be difficult. Fatigue is often a massive part of this disease. Disease severity ranges from person to person. Symptoms can come slowly, or they can come on quickly like flipping on a light switch. When that switch is turned on, it can seem like someone turned off your energy and personality. 

Janet Bauer

Myasthenia Gravis is considered the “snowflake” disease because every case is unique. Some people live a normal life that includes a career and family life, but for others with more severe symptoms, MG is their life and managing the disease is all they can fit into most of their days. While medications are available, finding the right one can take time and they don’t always work. It’s important to know that it’s not a one-size-fits-all disease and it can take time to diagnose and find a treatment plan that works. 

It’s an autoimmune and muscular disease that causes your voluntary muscles to weaken easily. With my permanently damaged right eye from MG, I point out MG can cause droopy eyelids and double vision. Swallowing and breathing struggles and using arms and legs can be challenging. I need to rest to get my strength back. 

Tammy Carter

I start by asking if the person has heard of MS (Multiple Sclerosis). The answer is almost always Yes!

From there, I explain the similarities of both diseases. Both MS and Myasthenia Gravis (MG) are autoimmune diseases that affect the neuromuscular and central nervous systems. In both conditions, the immune system mistakenly attacks healthy tissue. This can lead to symptoms like droopy eyelids, slurred speech (which can be so pronounced that people might think you’ve been drinking), muscle weakness, and fatigue in the face and jaw, making it difficult to chew and swallow. The key difference between these diseases is that MS primarily affects the spine and brain, while MG impacts the nerves and muscles.

Living with MG can be challenging. People often tell me, “You look normal, I’m sorry you are living with this disease.” My response is usually, “I don’t need sympathy, but awareness that this disease is rare and life-threatening.” I never take everyday tasks like brushing my teeth, combing my hair, or showering for granted. I’m thankful that I can still do these things and more for myself.

Gary Jackson 

Myasthenia Gravis (MG) is a muscle-weakening disease that affects the body and like a snowflake. It’s different for everyone in every way. Every muscle in the body can be affected by weakness, and the severity of muscle weakening differs from person to person. Physical activities accelerate the symptoms causing fatigue. For those of us with Ocular Myasthenia Gravis, we can struggle to keep our eyelids open, and we may experience double vision because of eyeball drifting. Every muscle associated with seeing can become fatigued to the point of shutdown. Imagine how MG might affect your mouth, throat muscles, arm and/or leg muscles or all these muscles simultaneously. Essentially, every muscle group in the body can be rendered unable to function properly if diagnosed with MG. This condition could lead to a life-threatening myasthenia gravis crisis, where a person may require ventilator support. 

Linda Loland 

My explanation of MG depends on who is asking. If I’m out in public and someone asks why I’m using a walker, my reply is to say I have a neuromuscular disorder. I never use the word “disease” because people generally back up a bit for fear it’s contagious. Sometimes, that’s good enough. But if they genuinely want to know more, I’ll tell them I have myasthenia gravis and briefly describe how signals are being blocked between my brain and certain muscles. If I’m looking pretty healthy when I share this information, and the individual looks skeptical, I do fall back on my MG crisis experience and how I spent four weeks in the hospital, the first week on a ventilator in ICU. I want people to understand how serious MG can be, even if we’re looking great at the moment.  

A few weeks ago, a woman approached me at the doctor’s office because we both had walkers. She became so interested in MG that she asked me to write down the name for her so she could go home and research it! I was so happy to have successfully educated someone about it.  

Joyce Holste 

I tell people that myasthenia gravis is a neuromuscular disease in which communication between the nerves and muscles are impaired. 

 

 

 

 

 

 

SeAndrea Ferguson 

People would perceive me as “normal” if I don’t tell them, and I don’t tell many people. I shared my story with others online and described it as a rare muscle disease that affects my voluntary muscles. My MG symptoms are less visible, so it’s hard for people to understand what I deal with daily. The hardest point to get across is that just because I’m younger doesn’t mean I don’t have my share of issues with this illness. I explained that I take medication every day just for my muscles to do their job. If I don’t take it or rest when I need to, my body will start to weaken and shut down. I emphasize rest as much as possible because my main symptom is general fatigue. I cannot do everything others my age do, which is frustrating. People forget I have MG. It’s important to know there is no ‘one size fits all’ treatment for MG. 

Victor Yipp 

I have this neuromuscular medical condition called Myasthenia Gravis. If I don’t mention this to others, most if not all people would perceive me as a normal person, taking into consideration my age (80). My only symptom is fatigue, for which I “prescribe” myself a daily nap of about an hour. I take no regular medications for MG. In 2017, I was diagnosed with the Anti-Musk version of MG, which is like a rare variant within a rare disease. Infusion with a specific medication (Rituxan/Rituximab) restored me to a condition of minimal symptoms. When I relapsed in 2022, the same treatment was given to me and again I responded successfully. I consider myself very fortunate. Most MG patients need some medication, even those with the same variant that I have. That may be why it’s called the “snowflake disease.” Everyone has to be treated individually. 

 

 

SeAndrea Ferguson, Board of Trustees

Meet New Board Member SeAndrea Ferguson

SeAndrea Ferguson is a wife, a mom, a teacher, an individual living with myasthenia gravis (MG) and member of Conquer MG’s Board of Trustees. She enjoys listening to music, reading, watching her favorite shows, and spending time with her amazing family and good friends.

Q: Where do you call home?

Ferguson: I live in Merrillville, IN.

Q: What is your MG Story?

Furguson: I was diagnosed with myasthenia gravis in 2003 when I was 18, so I’ve been living with and managing this disease for many years—and yet, I still have days when I struggle. I rest as needed and stay away from stressful situations or people. My family is very supportive, as are my caring and knowledgeable neurologists who help me manage the symptoms.

Q: What inspired you to join the Conquer MG Board of Trustees?

Ferguson: Until now, my engagement with Conquer MG has been as support group leader in northwest Indiana. I am eager to step into this new leadership role as a board member to continue helping others navigate the ups and downs of MG, and to help raise awareness of MG through story telling. Building awareness is proving to move the needle as evidenced by the increasing number of new treatments entering the market. It’s never a good time to be diagnosed with myasthenia gravis but as it happens, now is a good time to be diagnosed. But we need to make it easy for patients and caregivers to find support in their community.

MGNet Announces 2025 Scholars

The 2025 Myasthenia Gravis Rare Disease Network (MGNet) Scholar Awardees are Drs. Patricia Sikorski and Alexandra Bayer Wildberger.

Alexandra Bayer Wildberger, PhD, is a postdoctoral associate with Dr. Kevin O’Connor at Yale School of Medicine. She completed a Master in Molecular and Cellular Biology and a PhD in Cell Biology and Immunology at the Sorbonne University in Paris. Dr. Bayer Wildberger’s project proposes to investigate the molecular mechanisms through which autoreactive IgM may contribute to the pathology of acetylcholine receptor antibody-positive MG.

 

Patricia Sikorski, PhD, is a postdoctoral associate at George Washington University in the Laboratory for Myasthenia Gravis Research, which is directed by Dr. Linda Kusner. Dr. Sikorski completed a Masters and PhD in Microbiology and Immunology at Georgetown University and the National Institutes of Health. Dr. Sikorski’s project investigates the hypothesis that bias towards a stronger immune response in women drives enhanced differentiation into atypical B cell and dysregulated T cells in the thymus.

About MGNet

MGNet (mgnet.rarediseasesnetwork.org) is one of 20 NIH-funded Rare Disease Clinical Research Network sites. This provides a unique opportunity for myasthenia gravis to enhance all aspects of clinical research in the field and elevates the visibility in the scientific community, and in particular the rare disease community, which consists of nearly 7,000 rare diseases. In partnership with Conquer MG and the Myasthenia Gravis Foundation of America, the MGNet Pilot Studies Program provides funding for proposals that are highly innovative investigations in early stages of development.